2024
Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.
Corvese L, Weiss C, Huie S, Zhou B, Deng Y, Gong G, Kunz P, Fischbach N. Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials. Journal Of Clinical Oncology 2024, 42: e13586-e13586. DOI: 10.1200/jco.2024.42.16_suppl.e13586.Peer-Reviewed Original ResearchClinical trialsCancer clinical trialsTrial enrollmentPercentage of patientsYale Cancer CenterClinical trial enrollmentLimitations of clinical trialsTreating providersEnrolling patientsCancer CenterUnique patientsBreast programPatientsPatient-matchedEnrollment ratesStudy-related activitiesScreening toolTrial participantsTrialsCancerOffice staffClinicEnrollmentLanguage barriersNon-English
2014
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
James E, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky J, Fischbach N, Chang B, Salem R, Cha C, Stein S, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: e15226-e15226. DOI: 10.1200/jco.2014.32.15_suppl.e15226.Peer-Reviewed Original Research
2009
9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS)
Jahanzeb M, Fischbach N, Kosty M, Kumar P, Spigel D, Wozniak A, Teng S, Wang L, Sing A, Lynch T. 9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS). European Journal Of Cancer Supplements 2009, 7: 507. DOI: 10.1016/s1359-6349(09)71719-7.Peer-Reviewed Original Research
2008
Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS)
Lynch T, Brahmer J, Fischbach N, Garst J, Kumar P, Spigel D, Teng S, Vidaver R, Wang L, Navarro W. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS). Journal Of Clinical Oncology 2008, 26: 8077-8077. DOI: 10.1200/jco.2008.26.15_suppl.8077.Peer-Reviewed Original Research